<DOC>
	<DOCNO>NCT01642108</DOCNO>
	<brief_summary>Type 2 diabetes mellitus ( T2DM ) result early phase insulin secretory defect insulin resistance . Studies show population insulin resistance consider primary pathogenetic cause diabetes , high degree obesity primary insulin defect . Meanwhile , defective early insulin secretion play predominant role non-obese subtype T2DM include majority Japanese patient . Sitagliptin dipeptidyl peptidase-4 ( DPP-IV ) inhibitor indicate treatment T2DM . Sitagliptin increase plasma concentration active glucagon-like peptide-1 ( GLP-1 ) active glucose-dependent insulinotropic peptide ( GIP ) two- three-fold patient T2DM . The effect sitagliptin GLP-1 result low fast postprandial glucose concentration increase glucose dependent insulin release suppression inappropriate glucagon secretion . Namely , several mechanistic study use standardized meal show sitagliptin improve glucose control decrease glucagon level increase insulin concentration obese overweight T2DM patient BMI &gt; 25 kg/m2 . However , sitagliptin affect islet function , include glucagon secretion non-obese patient low insulin secretion know . Therefore , investigator examine effect sitagliptin glycemic control mechanism involve use standardized test meal non-obese Japanese patient T2DM whose BMI level &lt; 25 kg/m2 .</brief_summary>
	<brief_title>Treatment With Sitagliptin Non-obese Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Type 2 diabetic patient nonobese patient patient treated insulin therapy patient age less 20 year 90 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>